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A data-driven statistical 
model that estimates 
measurement uncertainty 
improves interpretation of ADC 
reproducibility: a multi-site study of 
liver metastases
Ryan Pathak1, Hossein Ragheb1, Neil A. Thacker1, David M. Morris1, Houshang Amiri2,5, Joost 
Kuijer  3, Nandita M. deSouza4, Arend Heerschap2 & Alan Jackson  1
Apparent Diffusion Coefficient (ADC) is a potential quantitative imaging biomarker for tumour cell 
density and is widely used to detect early treatment changes in cancer therapy. We propose a strategy 
to improve confidence in the interpretation of measured changes in ADC using a data-driven model that 
describes sources of measurement error. Observed ADC is then standardised against this estimation of 
uncertainty for any given measurement. 20 patients were recruited prospectively and equitably across 
4 sites, and scanned twice (test-retest) within 7 days. Repeatability measurements of defined regions 
(ROIs) of tumour and normal tissue were quantified as percentage change in mean ADC (test vs. re-
test) and then standardised against an estimation of uncertainty. Multi-site reproducibility, (quantified 
as width of the 95% confidence bound between the lower confidence interval and higher confidence 
interval for all repeatability measurements), was compared before and after standardisation to the 
model. The 95% confidence interval width used to determine a statistically significant change reduced 
from 21.1 to 2.7% after standardisation. Small tumour volumes and respiratory motion were found to 
be important contributors to poor reproducibility. A look up chart has been provided for investigators 
who would like to estimate uncertainty from statistical error on individual ADC measurements.
Diffusion weighted imaging (DWI) is a Magnetic Resonance Imaging (MRI) sequence acquisition that is sensitive 
to free water diffusion1,2. Regions of reduced extra-cellular space due to high cell density or other micro environ-
mental factors will result in restricted diffusion of free water relative to surrounding tissue. Similarly, increases 
in extravascular-extracellular space due to cell death may result in increased free water diffusion. Consequently, 
apparent diffusional coefficient (ADC) derived from diffusion weighted MRI has received considerable attention 
as a potential biomarker of early response to cytotoxic therapies3. The ADC is the decay constant, calculated 
from 2 or more DWI images, acquired with increasing sensitivity to water mobility. A high ADC corresponds to 
increased water mobility towards free diffusion, and conversely a low ADC corresponds to restricted diffusion. In 
a densely cellular homogeneous tumour, such as lymphoma, treatment-related ADC changes may be as high as 
50%4, however treatment responses may be heterogeneous due to regional micro environmental factors or genetic 
variation5–7. A recent animal model study of ovarian tumours showed an average 7.5% increase in mean ADC 
after treatment but identified significant spatial heterogeneity due to variations in tumour response7.
1University of Manchester, Wolfson Molecular Imaging Centre, Manchester, UK. 2Radboudumc, Radiology and 
Nuclear Medicine, Nijmegen, Gelderland, NL, Netherlands. 3VU University Medical Center, Physics & Medical 
Technology, PO Box 7057, Amsterdam, NL, 1007MB, Netherlands. 4Institute of Cancer Research, MRI Unit, Downs 
Road, Sutton, Surrey, SM2 5PT, UK. 5Neuroscience Research Center, Institute of Neuropharmacology, Kerman 
University of Medical Sciences, Kerman, Iran. Correspondence and requests for materials should be addressed to 
R.P. (email: ryan.pathak@manchester.ac.uk)
Received: 2 June 2017
Accepted: 9 October 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIeNtIfIC REPORTS | 7: 14084  | DOI:10.1038/s41598-017-14625-0
In therapeutic studies using ADC early treatment induced changes are typically in the range of 10–30%8,9. 
Statistically, in order to detect a 10% change in mean ADC for an individual lesion, with 95% reliability, a 
test-retest repeatability of 3–4% is required (assuming that the distribution of ADC measures is Gaussian). If 
repeatability is worse than this, then our ability to detect true biological change of this magnitude is lost. A 
repeatability of 3% may be difficult to achieve, particularly in multi-site, multi-vendor trials, although studies in 
phantoms and homogenous healthy liver taken across multiple sites, have shown repeatability of 1–4% and 3–7% 
respectively10. To our knowledge there is no published data to describe ADC reproducibility of liver metastases 
in a multi-site, multi-vendor setting.
Factors that negatively affect repeatability relate to the tumour itself (size11, heterogeneity12 and site13), image 
quality (signal to noise ratio (SNR)14, motion15), curve-fitting techniques16 and errors related to the MR system17. 
Voxel-wise quantitative DWI in the liver is also specifically degraded by respiratory motion artefact, with little 
improvement and mixed results when using on-table compensation methods such as navigator echo and res-
piratory gating18–20. Consequently, a change in ADC due to measurement errors may be interpreted as disease 
progression or response where response thresholds are derived from group-wise reproducibility data.
The primary endpoint of this study was to define a statistical model of predictable sources of variability that 
contribute to measurement error, and fit this to observed data in order to quantify the level of uncertainty in mean 
ADC repeatability. Through standardisation of repeatability measurements for predictable sources of statistical 
variability that contribute to uncertainty in the mean ADC, we sought to increase our confidence in detecting 
genuine post treatment changes for future studies. We have conducted this study in patients with colorectal liver 
metastases, which is a commonly studied pathology in novel therapeutic trials. There is considerable difference 
in the appearance and margination of metastases from different primary tumours and the potential impact of this 
will be discussed below.
Materials and Methods
Patients. This multi-site prospective study was compliant with; 1) Medical Research Involving Human 
Subjects Act (WMO) and approved by a certified Medical Ethics Committee (MEC) institutional review 
board at The VU University Medical Centre, Amsterdam, and Radboud University Nijmegen Medical Centre. 
2) Compliant with and approved by the NHS Health Research Authority Research Ethics Committee, United 
Kingdom, following approval from local Research & Development administrations at The Christie Hospital NHS 
Trust, Manchester, and The Royal Marsden Hospital NHS Trust, London. Formal written informed consent 
was recorded for each volunteer that participated. Inclusion criteria included; Histological diagnosis of primary 
colorectal carcinoma, radiological evidence of at least one liver metastasis (minimum volume 2 cm3), new diag-
nosis or no ongoing treatment. Exclusion criteria included; Contraindication to MRI, ongoing treatment. Patients 
who met the inclusion criteria were scanned consecutively, as and when they appeared at their respective oncol-
ogy clinic, prior to any new treatment commencing.
Image acquisition. Patients were imaged twice within 7 days, using 1.5T MR systems from 3 vendors 
(Table 1). DWI parameters were as follows; b value images for 3 orthogonal gradient directions, 4 signal aver-
ages per image, free-breathing single shot echo-planar sequence (SS-EPI), spectral attenuated inversion recov-
ery (SPAIR) fat suppression, 5 mm axial slice thickness, 40 slices with no inter-slice gap, target FOV of 380 mm 
(380 × 380 for GE, 384 × 384 for Philips and 332 × 380 for Siemens), bandwidth 1400–1800 Hz per pixel, pixel 
size of 1.5 × 1.5 mm, acquisition matrix 128 × 112 or 128 × 128.
Image analysis. A single lesion was chosen based on size (the largest visible single tumour or indistinguish-
able tumour conglomerate with a continuous circumference that was ≥2 cm3) and location (right lobe, away 
from the heart or diaphragm where possible). A single observer manually outlined whole tumour 3-dimensional 
(3D) regions of interest (ROI) from b-100 images for each test-retest measurement (Osirix v.5.8.2 32 bit viewing 
software) (Fig. 1). The first and last MRI slices through the tumour were excluded to minimise partial volume 
effects, whereby voxels at the edge of tumours contain both abnormal and normal tissue, resulting in artefactual 
reduction of tumour signal intensity. Automated or semi-automated selections of ROIs are widely used for areas 
of the body where movement artefact is less problematic, such as the brain21. Improvement in interobserver 
agreement from semi-automated methods can also be achieved in the liver22 however any reduction in the quality 
of acquisition (such as low SNR or motion artefact) will be associated with problems related to identification of 
the boundaries of the lesion. In patients with tumours that are highly heterogeneous automated methods may 
select only areas above a chosen threshold. Identification of outer boundaries from motion-affected tumours can 
also be problematic. Since our intention was to provide a proof of concept for the benefits of error modelling we 
MRI (1.5 T) Body coil
Parallel 
imaging
B-values 
(s/mm2)
TR/TE 
(ms)
Siemens Magnetom Avanto 6 channel GRAPPA 2 100, 500, 900 8000/76
General Electric (GE) 
Signa HDxt 8 channel ASSET
100, 500, 
900 8500/74
Philips Achieva 8 channel SENSE 0, 100, 500, 900 8000/88
Table 1. List of MR systems and receiver coils used, with variable DWI acquisition parameters.
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have chosen to use manual delineation of tumour volumes since this is the typical method used in the majority of 
studies of ADC in the liver2,23.
In order to develop and test the proposed error model (see below) we wished to maximise the range of ROI 
sizes available. Consequently, 2 additional single slice ROIs were defined within the delineated 3D tumour vol-
ume; 1) a slice representing the largest area through the lesion and 2) a slice that best represented mostly solid 
tumour. This reflects common practice in previous studies, for example where ADC metrics have been calculated 
from ROIs based on a single slice with the largest diameter24,25, or occasionally a prescribed 2D area believed to 
be solid tumour26. We could expect a single observer definition of the largest diameter slice within a tumour to 
be fairly robust, however the largest diameter slice normally contains the most central necrotic and cystic tissue. 
Although more subjective, a slice with the most solid tumour may be a better representation of cell density. It is 
important that we emphasise at this point, the primary purpose for defining further 2D small volume ROIs was to 
increase the accuracy of fit to our error model, and explore the relationship between statistical error and ROI size. 
Studies comparing 2D axial ROIs and prescribed ROIs, to 3D volumes11,22, have found whole tumour volumes to 
be more reproducible. Published consensus guidelines for diffusion imaging recommend 3D volumes27.
In addition, ROIs of a fixed dimension were defined over normal appearing liver parenchyma away from 
obvious tumour.
Voxel ADC values were estimated from the mono-exponential fit of 3 b-value images (100, 500, 900 s/mm2) 
corrected for high b-value SNR bias28 (see Supplementary information appendix 1). A frequency distribution 
histogram of ADC values within each ROI was generated, and a mean ADC for the whole ROI calculated (Fig. 1).
Statistical model of expected measurement error. The sample size chosen for this study, split equally 
between sites, is comparable to previous studies2,23. We have chosen to use percentage change in ADC (ΔADC%), 
which provides a metric of repeatability for individual tumour measurements that can be directly compared 
within and between studies29. This is an ideal repeatability metric for monitoring post treatment changes for 
individual patients. For comparison between studies, the 95% confidence interval width can be used to define 
statistically significant change in ADC measurements.
Assuming a Gaussian distribution of ADC the accuracy of any data-driven estimate of the mean value or of 
the distribution width will become more accurate as the sample size increases. Consequently, sample size in voxels 
(equivalent to tumour volume) would be expected to significantly influence the uncertainty in the measurement 
of mean ADC. Test-retest repeatability, expressed as individual tumour ΔADC% was therefore plotted against 
tumour volume expressed as the number of voxels in the tumour (log scale) to assess the relationship if any 
between tumour size and the sources of variation in repeated measures defined by our model (which contribute 
to measurement uncertainty). A single voxel volume, using the imaging protocol employed here is equivalent to 
11.25 mm3.
ΔADC%, (the percentage change in ADC between baselines, expressed as R12, provides a direct measure of 
repeatability between scans 1 and 2 and is calculated as
=
−
+
×
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where D1 and D2 are test and retest mean ADC values, respectively.
A proportion (εR12) of the measured repeatability between D1 and D2 is due to predictable statistical measure-
ment errors on D1 and D2, (σD1and σD2respectively). The term εR12can be thought of as a measure of the uncer-
Figure 1. Tumour selection and image analysis. A single lesion is chosen based on size and location from 
b-100 DWI images (right image) and a ROI is manually defined for each test-retest data set (middle image). 
A parametric map of ADC values is calculated for each pixel within the ROI (left image). For 3D volumes, the 
voxel ADC values within each slice ROI is combined and represented as a histogram (far left).
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tainty of the repeatability measurement and is estimated from error propagation of σD1and σD2 using the equation below (see Supplementary information appendix 2 for derivation)
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The term εR12 is dependent on the measurement accuracy of both the test and retest mean ADCs (σD1, σD2). 
Three parameters were defined within a model to describe εR12of the observed repeatability measurement. The 
simplest assumption is that εR12is due only to accumulation of systematic errors related to the MRI scanner. 
Systematic errors (εsys) contribute a fixed proportional error reflecting inability to accurately replicate equivalent 
image data on repeated attempts. Another possible source of measurement error reflects accuracy of the fitting 
routine used to estimate voxel ADC values; therefore a second parameter in our model assumes that these are 
fixed between D1 and D2. This is described as a fixed fitting error (σfix). The third parameter takes into considera-
tion the ADC histogram distribution width for D1 and D2. This is a measure of the accuracy of the calculated 
mean ADC (D1, D2). The standard error is the ratio between the standard deviation of the mean ADC, and the 
square root of the number of voxels within the ROI. The wider the distribution, the larger the standard error of 
the mean will be and conversely, the larger the sample size the smaller the standard error of the mean will be 
(hence the assumption earlier that ROI size is an important variable for repeatability). In addition to these factors, 
we would also expect ADC distribution width, and therefore mean ADC measurement accuracy, to be affected by 
SNR and tumour heterogeneity.
In summary, the 3-parameter model of statistical measurement errors include a fixed fitting error term (σfix), 
a term (β) proportional to ADC width and the systematic error (εsys), as described in the following equation
ε β ε σ σ ε σ σ ε= + + .( , ) ( , ) (1 3)R R D D R fix fix sys
2 2 2 2 2
12 12 1 2 12
A maximum likelihood expectation (MLE) routine was used to fit this general model to the defined 3D and 
2D single slice ROIs in order to identify the parameter(s) most predictive of the repeatability measurements 
obtained (refer to Supplementary information appendix 3). The observed ΔADC% was standardised to εR12in order to produce an estimate of reproducibility for the entire group (95% confidence interval widths). In other 
words, the level of uncertainty in the repeated measures for each ROI was taken into consideration. The parame-
ters (β, σfix and εsys) that produced the best fit of the data were used to generate a look-up chart for estimating the 
relationship between εR12and the ADC histogram width, for a range of ROI sizes.Datasets identified as having visible motion artefact were excluded from the MLE model fitting routine as we 
hypothesise that respiratory motion is an important additional variable affecting reproducibility, independently 
from the model. Once the best-fit parameters were obtained, all data including those with visible motion were 
included to compare the reference standard to the index test (data standardised to the level of uncertainty in each 
observed ΔADC%). A chi-squared goodness of fit method was applied to test the suitability of the error model 
as a fit for the observed data.
Data availability. The full dataset of mean and median ADC values calculated from all the ROIs defined for 
this study, are freely available within the following document:http://www.tina-vision.net/docs/memos/2014-007.
pdf
Results
Twenty patients (5 per site) were scanned between May 2012 and October 2014 (16 males, 4 females; median age 
63 years; range 44–77 years). 5 patient data sets (25%) were identified with visible motion in test, retest or both 
acquisitions. Table 2 is a summary of the following; test-retest average tumour size (voxels), average absolute 
mean ADC values, the percentage change in tumour size (ΔVOL%) and ADC (ΔADC%) for each patient.
The average whole tumour mean ADC was 109 × 10−5 mm2/s (range 76–198 × 10−5 mm2/s).
The observed ΔADC% for each test-retest dataset is plotted against ROI size in Fig. 2. There is a trend in the 
scatter to suggest repeatability improves with increasing ROI volume, but the overall 95% confidence limit width 
for all data is 21.1%. The ROI volumes delineated between test-retest data are relatively stable (Table 2), with a 
mean ΔVOL% of 0.6% (SD 8.2%). The 95% confidence limit width for ΔVOL% is 16.1%. When 2 extreme outli-
ers are removed, this becomes 8.2% for the remaining 18 test retest datasets.
Applying the 3-parameter model. The contribution of predictable statistical errors to each ΔADC% was 
estimated using the 3-parameter model described above. The parameters (scaling factors) in the error model were 
found to be:
β σ ε= . = . = .and4 87, 69 35 2 65fix sys
In the majority of cases β had a larger contribution to the measurement error than σfix. In most cases was 
minimal. When σfix was removed (i.e. a 2 parameter model), β = 5.48 and εsys = 3.89.
The suitability of the error model (i.e. a null hypothesis that the model describes the data accurately) was 
tested using the Chi-squared (χ2) method (see appendix 3 of the Supplementary information). For 3D tumour 
ROIs, the χ2 = 11.33 with 15 degrees of freedom (Probability that the null hypothesis is accepted = 0.73). As there 
was no significant difference between our model and the observed data (p > 0.05), the null hypothesis was 
accepted. For the 2-parameter model, for 3D ROIs = 8.79, (p = 0.89) which was marginally worse than when σfix 
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had been included. When only using εsys (i.e. assuming a conventional form where measurement error is simply 
constant across samples) the model was rejected (p = 0.03).
The relationship between the product of the 3-parameter model, εR12, and ROI size was plotted for each data 
set (Fig. 3). There is a clear inverse relationship between expected statistical error and ROI volume. The εR12 
improved, despite motion, as tumour size increased. Above a threshold value of approximately 22.5 cm3 (dashed 
line in Fig. 3), the rate of improvement began to plateau.
When ΔADC% is standardized to its corresponding estimated statistical measurement error, i.e. factoring out 
the differences in the contribution of statistical measurement error on each ΔADC% (Fig. 4), the 95% confidence 
interval width used to determine a statistically significant change in ΔADC% reduced from 21.1 to 2.7%. The 
majority of data affected by gross motion become outliers, regardless of their size.
Using the 3-parameter approach, when the ΔADC% for each ROI used to fit the model, is standardised to 
its level of uncertainty, the χ2 distribution is 59.95 with 60 degrees of freedom (Probability (χ2) ≤ 59.95 = 0.48), 
i.e. there was no significant difference between the standardised distribution and our model, and the data was a 
good fit. When grouping all tumour ROIs together, χ2 istribution is 132 with 15 degrees of freedom (Probability 
Patient Voxels* ΔVOL% ADC* ΔADC% Lesion Image
1 1141 0.44 76 18.56 Motion
2 3214 8.47 102 −22.37 Sub-phrenic Motion
3 2845 0.21 97 1.17 5% cystic
4 1297 0.15 77 14.69
5 603 4.81 98 −3.39 Sub-phrenic Motion
6 573 2.44 87 −2.52
7 148 −14.63 123 2.25
8 3178 −1.48 102 7.60 Sub-phrenic Motion
9 4589 1.44 95 −4.35
10 3731 28.19 103 1.69
11 5957 0.32 140 6.48
12 74572 −6.04 102 −12.13 Motion
13 6780 −4.09 93 1.22
14 270 −5.57 93 −7.36
15 61130 −5.01 118 −1.11
16 8788 4.79 127 −5.30 10% cystic
17 4315 −4.82 98 1.06
18 2140 −2.38 129 1.04
19 7914 8.38 198 2.84 95% cystic
20 4304 −3.53 110 −0.31
Table 2. The ADC values, lesion size and image characteristics for each patient. For 3D whole tumour volumes, 
the average (*) of two baselines is displayed for; number of voxels (where each voxel is 11.25 mm3), mean ADC 
values (×10−5 mm2/s). The percentage change in tumour volume and mean ADC between test-retest is given 
(ΔVOL%, ΔADC%). The data sets visually affected by “Motion” artefact are indicated in the Image column.
Figure 2. Tumour reproducibility of ΔADC% as measured by the 95% confidence interval width for all 
multisite data. ∆ADC% is plotted against ROI size (log number of voxels) for 3D and 2D tumour regions (3D 
circles, 2D triangles). Data affected by motion is highlighted (solid black). The fixed-sized normal parenchyma 
ROIs are included in the calculation of the 95% CI width of 21.1%.
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χ2 ≤ 132 = 2.4852e–7), therefore the model is rejected. This is to be expected, as data sets with motion artefact are 
included. When grouping only those tumour ROIs without visible motion, χ2 distribution is 46 with 45 degrees 
of freedom (Probability (χ2) ≤ 46 = 0.43), and the model is once more a good fit.
In Fig. 5 a look up chart is presented that can be used to estimate εR12 for any ROI with a known ADC histo-
gram width (SD) and size (voxels). This was developed using the parameters (β, σfixand εsys) that produced the 
best fit of data. For example, if an investigator measures ΔADC% of a tumour after treatment to be 25%, and the 
tumour volume is between 10 and 20 cm3, the uncertainty in that estimation of ΔADC% will be approximately 
between 6 and 18%. This can be quantified more accurately by knowing the ADC distribution width for the ROI 
histogram. If the standard deviation of the ADC distribution is large e.g. 50 mm/s2, then uncertainty is the meas-
urement is around 18%. In comparison, if there is a narrower ADC distribution width for a tumour volume, e.g. 
10 mm/s2, then the investigator can have more confidence in the ΔADC% measurement of 25% after treatment 
(approximately 6% uncertainty in the measurement).
In summary, for a small tumour volume, with a wide ADC range of distribution, a higher threshold is required 
in the interpretation of ΔADC%, in order to overcome uncertainty in the measurement.
Discussion
Mean ADC is a potential MR imaging biomarker for use in assessment of early treatment response of colorectal 
liver metastasis3. In therapeutic trials early treatment typically induce ADC changes in the range of 10–30%8,9. 
As discussed in the introduction, in order to reliably detect a 10% change in a single lesion requires an accuracy 
Figure 3. The relationship between statistical measurement error and tumour ROI size. Measurement error 
improves with increasing ROI size, up to a threshold of around 2000 voxels equivalent to 22.5 cm3.
Figure 4. The improvement in estimating repeatability measurements after accounting for the contribution of 
statistical measurement error. ∆ADC% is plotted against ROI size (log scale of number of voxels) for 3D and 
2D tumour regions (3D circles, 2D triangles). Data affected by motion is highlighted (solid black). When the 
contribution of statistical measurement error is factored out (compared to Fig. 2), the 95% confidence interval 
width improves from 21.1% to 2.7%. The majority of data affected by motion become outliers, regardless of their 
size.
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of ADC measurements sufficient to produce test-retest repeatability of 3–4%. In this prospective multi-site, 
multi-vendor study ΔADC% reproducibility for all tumour ROIs was 21.1% (95% confidence interval width). 
This compares slightly favourably but to a similar degree, to a previous study that found limits of agreement 
between 28.7 and 31.3% for short-term reproducibility30. For completion, Coefficient of Variance (CoV) was cal-
culated using absolute mean ADC values. A multi-site CoV of 5.3% was comparable to previous single site studies 
that have measured reproducibility in healthy liver10,15,31–35, or liver tumours30,34,36,37 using 1.5T or 3T scanners 
with a variety of protocols and gating methods. The average whole tumour, mean ADC values from this study 
of 109 × 10−5 mm2/s (range 76–198 × 10−5 mm2/s) agree closely with those previously published for colorectal 
metastases2,23.
Any estimate of ADC will be subject to uncertainty from a variety of sources. It is clear from our observations 
that motion is one of the major sources of error in ADC measurements. This work did not address the movement 
issue since movement effects cannot be modeled as a fixed error in the parametric images. Another potential 
source of error is the choice of delineation methods used for identification of ROIs. In this paper we have used 
manual delineation since is the most commonly employed2,23 and has been recommended in consensus reviews27. 
Automated methods which may provide improved accuracy have been widely employed in tissue not subject 
physiological motion, particularly in studies in the brain21. To date, studies of liver tumours have not widely 
employed automated methods and would require the highest quality images to accurately delineate tumour 
boundaries. In the current study the average percentage change in tumour volume measurements between base-
lines was 0.6% (SD 8.2%). It is possible that a combination of effective motion correction and automated tumour 
delineation could improve this. However, improved margin delineation would only be expected to produce fur-
ther improvements in ADC reproducibility above the 2.7% that we have achieved here.
We applied a 3-parameter model, which includes terms for systematic, MR system related, errors; fitting errors 
in the ADC estimation and statistical errors arising from inaccuracies in estimating mean ADC. In data where 
there was no visible movement artefact the largest source of predictable measurement error resulted from differ-
ences in the standard error on the mean, estimated from ADC histograms. Consequently, statistical measurement 
error was much larger in smaller tumours. When the ROI volume is larger than approximately 22.5 cm3, the ben-
efit of reduced uncertainty with increased tumour volume begins to plateau.
The 95% confidence limit width for ΔADC% in raw data is 21.1% falling to 2.7% when the estimated ADC 
values were standardised to the estimated statistical measurement uncertainty. The remaining variability between 
test and retest values can be attributed to a combination of factors not included in the model (e.g. motion, tumour 
heterogeneity, SNR). Clearly our error model makes an assumption that the original datasets are accurately 
co-registered and does not account for movement artefact.
When data is standardised against uncertainty in individual repeatability measurements a number of ROIs 
affected by motion become outliers (Fig. 4) with the ΔADC% of the remaining ROIs lying mostly within 2% of 
zero bias. It is clear that accurate interpretation of the observed changes must account for or preferably correct for 
the level of uncertainty in a repeatability measurement for individual tumours. Following this, the contributing 
effect of respiratory motion to poor reproducibility and false positive results, can be more accurately assessed. In 
the current dataset 25% of the data was affected by visible motion artefact.
The development of the error model has very significant implications in the interpretation of ADC data, 
which is likely to be equally true in other anatomical settings. Use of the model either directly, or by estima-
tion of uncertainty from the lookup table (Fig. 5) enables the investigator to understand the expected statistical 
errors in individual estimates of mean ADC based on the number of voxels in the sample, combined with the 
standard deviation of the ADC distribution within the ROI. The lookup table can be used directly to assess the 
likely significance of any change in ADC observed in a single tumour as a result of physiological, pathological or 
therapeutic response. For group studies, the model may be used to assess reproducibility and therefore significant 
change thresholds with greater confidence, by standardising the observed data to the level of uncertainty in the 
measurement. The model may also be used to justify the selection of minimal tumour size in order to minimise 
measurement uncertainty.
Figure 5. Look up chart for estimating statistical error. Using the parameters that produced the best fit of data, 
a look-up chart has been created, that can be utilised to estimate statistical measurement error for any ROI with 
a known ADC histogram width (SD) and size (voxels).
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We have presented this work as a proof of concept of the potential benefits for the application of error model-
ling to improve sensitivity to therapeutic or physiological change. We conducted the study in patients with met-
astatic colorectal carcinoma where metastases tend to be relatively well delineated and typically show significant 
signal intensity variation from normal background38. Metastatic lesions from other biological sources can show 
a wide variation in imaging characteristics and signal intensity39. Choosing a specific type of tumour metastasis 
with a relatively consistent imaging morphology limits variability from sources not included in the error model. 
The conclusions drawn here concerning the impact of tumour volume on measurement accuracy will apply for 
all types of tumour, although additional errors may be expected in cases where there is biological difficulty with 
ROI delineation. It will be important for individual studies to assess interobserver variability in ROI delineation 
and to develop reproducible manual, automated or semi-automated methods for detection of tumour margins. 
Similarly, alterations in local tissue vascularisation or peri-tumoural tissue density may affect the reproducibility 
of ROI delineation in individual cases or following therapy, affecting sensitivity to changes in tumoural ADC. 
Appropriate error modelling using the techniques described here can still be expected to deliver similar improve-
ments in sensitivity.
The modelling techniques described here are applied directly to calculated parametric images. Sources of error 
in the calculation of the parametric image are not addressed and cannot be addressed in this methodological 
approach. There is therefore a clear need to perform quality control which must, in any clinical study, include 
detection of and correction of physiological or patient motion prior to the calculation of parametric images. 
In this study we have deliberately excluded tumours from areas where significant motion would be expected in 
order to provide data to test the error model concept. Despite this, we have identified visible motion in almost 
25% of tumours. Most of these were tumours in the sub-phrenic region (Table 2). Errors resulting from failure to 
correct the motion artefact were ameliorated by the improved statistical power in large tumours but had a very 
significant detrimental effect on the estimation of ADC reproducibility in smaller lesions. We would assume that 
in clinical studies appropriate motion correction would be performed or, based on these findings and those of 
previous studies, that datasets showing significant motion artefact would be excluded. A number of data regis-
tration methods to correct for movement during data acquisition, prior to calculation of parametric images, have 
been described and are readily available40.
The findings presented here identify several methodological approaches that are essential to improve sen-
sitivity to therapeutic or physiological change. Firstly; it is essential that extraneous motion be identified and 
corrected prior to calculation of parametric images. Any error introduced by motion cannot be addressed or 
corrected following the calculation of the ADC map. Secondly; significant reductions in sensitivity to change 
are associated with smaller tumours. These effects are significant below a tumour size of approximately 22.5 cm³. 
Clearly exclusion of tumours below this size is undesirable and impractical in most clinical applications. It is 
impossible to identify a single "cut-off " volume that should be applied across clinical studies. If the expected 
magnitude of change in ADC is known, or where a threshold for detection sensitivity is desired then the use 
of the error model can provide a recommended minimum tumour volume for individual studies. This can be 
approximated by use of the lookup table provided in Fig. 5. This approach should be used to identify inclusion/
exclusion criteria for individual studies. Thirdly; application of the error model within a clinical study will allow 
significant reductions in minimum tumour size due to the consequent improvements in sensitivity for detection 
of change in ADC.
Our study has a number of limitations. The multi-site nature of the design meant that each site had to follow a 
standardised protocol that may not represent the optimal results available from individual manufacturers system. 
We did not attempt to quantify inter observer reliability which is likely to be another source of variability in future 
study designs. We have not attempted to correct for the clear visible motion artefact in a subset of the patients, 
which we have shown to be a significant contribution to reduced accuracy in estimates of ADC. This reflects the 
lack of an effective motion correction technique, which must form a priority for subsequent methodological 
research in this area.
Conclusion
We have presented a model that describes statistical sources of variation, and illustrate how this can be used to 
determine the level of uncertainty in a repeatability measurement of ADC for an individual tumour based on 
the ROI size and the standard deviation of the ADC distribution. We have standardised observed data to their 
level of uncertainty, a method that can be used for group studies, to estimate with more accuracy the confidence 
limits (95% confidence interval widths) that would determine a statistically significant change in ADC. For small 
tumour volumes with a wide ADC range of distribution, measurements are likely to have a high degree of uncer-
tainty. A strategy of minimum tumour size could optimise statistical power from group studies. For individual 
tumour assessment, a higher threshold is required in the interpretation of ΔADC%, in order to overcome uncer-
tainty in the measurement. We provide a lookup chart to allow investigators to estimate uncertainty due to sta-
tistical error, for any given tumour volume and distribution. Finally, we have also demonstrated that movement 
artefact is a major remaining source of error suggesting that our technique should be combined with appropriate 
motion correction strategies, particularly for small tumours40.
References
 1. Le Bihan, D. & Johansen-Berg, H. Diffusion MRI at 25: exploring brain tissue structure and function. NeuroImage 61, 324–341, 
https://doi.org/10.1016/j.neuroimage.2011.11.006 (2012).
 2. Deckers, F. et al. Apparent diffusion coefficient measurements as very early predictive markers of response to chemotherapy in 
hepatic metastasis: a preliminary investigation of reproducibility and diagnostic value. Journal of magnetic resonance imaging: JMRI 
40, 448–456, https://doi.org/10.1002/jmri.24359 (2014).
www.nature.com/scientificreports/
9SCIeNtIfIC REPORTS | 7: 14084  | DOI:10.1038/s41598-017-14625-0
 3. Sinkus, R., Van Beers, B. E., Vilgrain, V., DeSouza, N. & Waterton, J. C. Apparent diffusion coefficient from magnetic resonance 
imaging as a biomarker in oncology drug development. European journal of cancer 48, 425–431, https://doi.org/10.1016/j.
ejca.2011.11.034 (2012).
 4. Huang, W. Y. et al. Diffusion-Weighted Imaging for Predicting and Monitoring Primary Central Nervous System Lymphoma 
Treatment Response. AJNR. American journal of neuroradiology. https://doi.org/10.3174/ajnr.A4867 (2016).
 5. O'Connor, J. P. et al. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clinical cancer 
research: an official journal of the American Association for. Cancer Research 21, 249–257, https://doi.org/10.1158/1078-0432.CCR-
14-0990 (2015).
 6. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England journal 
of medicine 366, 883–892, https://doi.org/10.1056/NEJMoa1113205 (2012).
 7. Tourell, M. C. et al. The distribution of the apparent diffusion coefficient as an indicator of the response to chemotherapeutics in 
ovarian tumour xenografts. Sci Rep 7, 42905, https://doi.org/10.1038/srep42905 (2017).
 8. Cui, Y., Zhang, X. P., Sun, Y. S., Tang, L. & Shen, L. Apparent diffusion coefficient: potential imaging biomarker for prediction and 
early detection of response to chemotherapy in hepatic metastases. Radiology 248, 894–900, https://doi.org/10.1148/
radiol.2483071407 (2008).
 9. Koh, D. M. et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR. 
American journal of roentgenology 188, 1001–1008, https://doi.org/10.2214/AJR.06.0601 (2007).
 10. Winfield, J. M. et al. A framework for optimization of diffusion-weighted MRI protocols for large field-of-view abdominal-pelvic 
imaging in multicenter studies. Medical physics 43, 95, https://doi.org/10.1118/1.4937789 (2016).
 11. Lambregts, D. M. et al. Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver 
variability. European radiology 21, 2567–2574, https://doi.org/10.1007/s00330-011-2220-5 (2011).
 12. Asselin, M. C., O'Connor, J. P., Boellaard, R., Thacker, N. A. & Jackson, A. Quantifying heterogeneity in human tumours using MRI 
and PET. European journal of cancer 48, 447–455, https://doi.org/10.1016/j.ejca.2011.12.025 (2012).
 13. Schmid-Tannwald, C. et al. Diffusion-weighted MR imaging of focal liver lesions in the left and right lobes: is there a difference in 
ADC values? Academic radiology 20, 440–445, https://doi.org/10.1016/j.acra.2012.10.012 (2013).
 14. Schmidt, H., Gatidis, S., Schwenzer, N. F. & Martirosian, P. Impact of measurement parameters on apparent diffusion coefficient 
quantification in diffusion-weighted-magnetic resonance imaging. Investigative radiology 50, 46–56, https://doi.org/10.1097/
RLI.0000000000000095 (2015).
 15. Kwee, T. C., Takahara, T., Koh, D. M., Nievelstein, R. A. & Luijten, P. R. Comparison and reproducibility of ADC measurements in 
breathhold, respiratory triggered, and free-breathing diffusion-weighted MR imaging of the liver. Journal of magnetic resonance 
imaging: JMRI 28, 1141–1148, https://doi.org/10.1002/jmri.21569 (2008).
 16. Winfield, J. M. et al. Modelling DW-MRI data from primary and metastatic ovarian tumours. European radiology 25, 2033–2040, 
https://doi.org/10.1007/s00330-014-3573-3 (2015).
 17. Malyarenko, D. et al. Multi-system repeatability and reproducibility of apparent diffusion coefficient measurement using an ice-
water phantom. Journal of magnetic resonance imaging: JMRI 37, 1238–1246, https://doi.org/10.1002/jmri.23825 (2013).
 18. Kandpal, H., Sharma, R., Madhusudhan, K. S. & Kapoor, K. S. Respiratory-triggered versus breath-hold diffusion-weighted MRI of 
liver lesions: comparison of image quality and apparent diffusion coefficient values. AJR. American journal of roentgenology 192, 
915–922, https://doi.org/10.2214/AJR.08.1260 (2009).
 19. Nasu, K., Kuroki, Y., Sekiguchi, R. & Nawano, S. The effect of simultaneous use of respiratory triggering in diffusion-weighted 
imaging of the liver. Magnetic resonance in medical sciences: MRMS: an official journal of Japan Society of Magnetic Resonance in 
Medicine 5, 129–136 (2006).
 20. Taouli, B. et al. Diffusion-weighted imaging of the liver: comparison of navigator triggered and breathhold acquisitions. Journal of 
magnetic resonance imaging: JMRI 30, 561–568, https://doi.org/10.1002/jmri.21876 (2009).
 21. Ellingson, B. M., Bendszus, M., Sorensen, A. G. & Pope, W. B. Emerging techniques and technologies in brain tumor imaging. 
Neuro-oncology 16(Suppl 7), vii12–23, https://doi.org/10.1093/neuonc/nou221 (2014).
 22. Bonekamp, D. et al. Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment 
response in hepatocellular carcinoma. European journal of radiology 83, 487–496, https://doi.org/10.1016/j.ejrad.2013.11.016 
(2014).
 23. Heijmen, L. et al. Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation. 
European radiology 23, 748–756, https://doi.org/10.1007/s00330-012-2654-4 (2013).
 24. Surov, A. et al. Diffusion-Weighted Imaging in Meningioma: Prediction of Tumor Grade and Association with Histopathological 
Parameters. Translational oncology 8, 517–523, https://doi.org/10.1016/j.tranon.2015.11.012 (2015).
 25. Xu, X. Q. et al. Diffusion Weighted Imaging for Differentiating Benign from Malignant Orbital Tumors: Diagnostic Performance of 
the Apparent Diffusion Coefficient Based on Region of Interest Selection Method. Korean journal of radiology 17, 650–656, https://
doi.org/10.3348/kjr.2016.17.5.650 (2016).
 26. Kono, K. et al. The role of diffusion-weighted imaging in patients with brain tumors. AJNR. American journal of neuroradiology 22, 
1081–1088 (2001).
 27. Padhani, A. R. et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. 
Neoplasia 11, 102–125 (2009).
 28. Gudbjartsson, H. & Patz, S. The Rician distribution of noisy MRI data. Magnetic resonance in medicine 34, 910–914 (1995).
 29. Hoang, J. K. et al. Diffusion-weighted imaging for head and neck squamous cell carcinoma: quantifying repeatability to understand 
early treatment-induced change. AJR. American journal of roentgenology 203, 1104–1108, https://doi.org/10.2214/AJR.14.12838 
(2014).
 30. Kim, S. Y. et al. Malignant hepatic tumors: short-term reproducibility of apparent diffusion coefficients with breath-hold and 
respiratory-triggered diffusion-weighted MR imaging. Radiology 255, 815–823, https://doi.org/10.1148/radiol.10091706 (2010).
 31. Bilgili, M. Y. Reproductibility of apparent diffusion coefficients measurements in diffusion-weighted MRI of the abdomen with 
different b values. European journal of radiology 81, 2066–2068, https://doi.org/10.1016/j.ejrad.2011.06.045 (2012).
 32. Braithwaite, A. C., Dale, B. M., Boll, D. T. & Merkle, E. M. Short- and midterm reproducibility of apparent diffusion coefficient 
measurements at 3.0-T diffusion-weighted imaging of the abdomen. Radiology 250, 459–465, https://doi.org/10.1148/
radiol.2502080849 (2009).
 33. Corona-Villalobos, C. P. et al. Agreement and reproducibility of apparent diffusion coefficient measurements of dual-b-value and 
multi-b-value diffusion-weighted magnetic resonance imaging at 1.5 Tesla in phantom and in soft tissues of the abdomen. Journal 
of computer assisted tomography 37, 46–51, https://doi.org/10.1097/RCT.0b013e3182720e07 (2013).
 34. Larsen, N. E., Haack, S., Larsen, L. P. & Pedersen, E. M. Quantitative liver ADC measurements using diffusion-weighted MRI at 3 
Tesla: evaluation of reproducibility and perfusion dependence using different techniques for respiratory compensation. Magma 26, 
431–442, https://doi.org/10.1007/s10334-013-0375-6 (2013).
 35. Rosenkrantz, A. B., Oei, M., Babb, J. S., Niver, B. E. & Taouli, B. Diffusion-weighted imaging of the abdomen at 3.0 Tesla: image 
quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla. Journal of magnetic resonance imaging: JMRI 33, 
128–135, https://doi.org/10.1002/jmri.22395 (2011).
www.nature.com/scientificreports/
1 0SCIeNtIfIC REPORTS | 7: 14084  | DOI:10.1038/s41598-017-14625-0
 36. Koh, D. M. et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 
phosphate and bevacizumab in a two-centre phase I clinical trial. European radiology 19, 2728–2738, https://doi.org/10.1007/
s00330-009-1469-4 (2009).
 37. Kim, S. Y. et al. Reproducibility of measurement of apparent diffusion coefficients of malignant hepatic tumors: effect of DWI 
techniques and calculation methods. Journal of magnetic resonance imaging: JMRI 36, 1131–1138, https://doi.org/10.1002/
jmri.23744 (2012).
 38. Sica, G. T., Ji, H. & Ros, P. R. CT and MR imaging of hepatic metastases. AJR. American journal of roentgenology 174, 691–698, 
https://doi.org/10.2214/ajr.174.3.1740691 (2000).
 39. Namasivayam, S., Martin, D. R. & Saini, S. Imaging of liver metastases: MRI. Cancer imaging: the official publication of the 
International Cancer Imaging. Society 7, 2–9, https://doi.org/10.1102/1470-7330.2007.0002 (2007).
 40. Ragheb, H. et al. The Accuracy of ADC Measurements in Liver Is Improved by a Tailored and Computationally Efficient Local-Rigid 
Registration Algorithm. PloS one 10, e0132554, https://doi.org/10.1371/journal.pone.0132554 (2015).
Acknowledgements
The research leading to these results has received support from the Innovative Medicines Initiative Joint 
Undertaking (www.imi.europa.eu) under grant agreement number 115151, resources of which are composed 
of financial contribution from the European Unions Seventh Framework Programme (FP7/2007–2013) and 
EFPIA companies in-kind contribution. There was, however, no financial or in-kind contribution from EFPIA 
companies to the research specifically described in this paper. The funders of the research leading to these results 
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Contributions
We are submitting original research with data that has not yet been published in any journal. We declare that all 
named authors have read the manuscript and have agreed to submit in its present form. All named authors have 
made a sufficient contribution to the work. R.P. has been involved with the recruitment, data acquisition, analysis 
and writing of the first draft. H.R. has been involved with the data analysis and development of the statistical error 
model, as well as being heavily involved in the writing process. N.T. has been heavily involved in the design and 
supervision of the statistical error model and data analysis. D.M. was responsible for design and implementation 
of the standardized M.R.I. protocol for the overall project. The authors, J.K. and H.A. have been involved in 
protocol development, data recruitment, second and subsequent draft edits. The authors A.H., N.D. and A.J. have 
provided input into writing and editing of the manuscript and overall supervision and invaluable guidance.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-14625-0.
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
